Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Regorafenib After Failure of First-Line Immune Checkpoint Inhibitor-Based Combination Therapy in Child-Pugh B Patients With HCC: A Phase 2 RECOMEND Trial

NCT07514455 is registered in ClinicalTrials.gov with Ju Hyun Shim as lead sponsor.

NCT NCT07514455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07514455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Regorafenib After Failure of First-Line Immune Checkpoint Inhibitor-Based Combination Therapy in Child-Pugh B Patients With HCC: A Phase 2 RECOMEND Trial
Lead sponsor
Ju Hyun Shim
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 15, 2026
Completion date
June 30, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular, disease progression, hepatic insufficien, treatment failure